Aktuelle Therapien und Technologien in der Kinderdiabetologie

ZUSAMMENFASSUNG

In diesem Artikel soll eine kurze Zusammenfassung gegeben werden über einige aktuelle Neuerungen in der Diabetestherapie bei Kindern und Jugendlichen. Angefangen von der Vorstellung neuer Insuline und deren Einsatzmöglichkeiten in der ICT mit Vor- und Nachteilen geht es auch um neue Insulinpumpenmodelle und deren Anwendungsmerkmale bis hin zu FGM, CGM und zur sensorunterstützten Pumpentherapie, deren letztendliche Anwendung in einem Hybrid-Closed-Loop endet. Die komplette Anwendung beim Patienten ist noch nicht für alle vorgestellten Neuerungen möglich, aber in Aussicht oder möglichweise das Ziel.

ABSTRACT

In this paper we would like to give a comprehensive overview on new diabetes technologies in treatment of children and adolescents. New insulins and their use in intensive insulin treatment are discussed with their pros and cons. Insulin pumps also improved regarding combination with continuous glucose monitoring (CGM) or intermittent scanning CGM and sensor augmented pump therapy. These innovations lead to newest developed hybrid closed loop systems. These systems are still not available but will be soon on the market for whole Europe.

Schlüsselwörter

Diabetestherapie - Insulin - Insulinpumpen - FGM - CGM - SuP

Keywords

Diabetes therapy - insulin - insulin pump - FGM - CGM - sensor augmented pump therapy

• Literatur

• 1 Danne T, Ziegler R, Kapellen T. Diabetes bei Kindern und Jugendlichen; Deutscher Gesundheitsbericht Diabetes, 2019; Deutsche Diabetes Gesellschaft. 2019 S 124-125
• 2 Heise T, Pieber TR, Danne T. et al A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamics characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clinical pharmacokinetics 2017; 56 (05) 551-559
• 3 Russell-Jones D, Bruce W, Bode BW, De Block C. et al Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes Care 2017; 40 (07) 943-950
• 4 Preumont V, Buysschaert M. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials. Diabetes & Metabolism 2019 pii: S1262–3636(19)30067–30069
• 5 Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab 2017; 19 (01) 3-12
• 6 Heise T. et al Insulin degludec: four times lower pharmacodynamics variability than Insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14 (09) 859-864
• 7 Lane W, Bailey TS, Gerety G. et al Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318 (01) 33-44
• 8 Blevins TC DahD, Rosenstock J. et al Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus^® in patients with type 1 diabetes in a randomized controlled trial; the ELEMENT 1 study, Diabetes, Obesity and Metabolism. 2015; 17 (08) 726-733
• 9 Karges B, Schwandt A, Heidtmann B. et al Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 2017; 318: 1358-1366
• 10 Böttcher C, Schäfer M, Kamrath C. et al Erfahrungen eines Pädiatrischen Zentrums mit ‚mylife^™ OmniPod^®‘ Patch Pump erster Generation.Diabetologie und Stoffwechsel. 2012: 7-73
• 11 Ziegler R, Adolfsson P, Kamecke U. et al Insulin pump therapy in children: bolus dosing accuracy of different insulin pumps. ISPAD, 2016 Valencia, Abstract P033. Pediatric Diabetes 2016; 17 24 49
• 12 Singler EM. Insulinabgabegenauigkeiten von Patch-Pumpen versus Schlauchpumpen – eine systematische Analyse unter Laborbedingungen. DOI: 10.6094/UNIFR/149352
• 13 Edge J, Acerini C, Campbell F. et al An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child 2017; 102: 543-549
• 14 Massa GG, Gys I, Op t, Eyndt A. et al Evaluation of the Freestyle Libre Flash Glucose Monitoring system in children and Adolescents with Type 1 Diabetes; Horm Res Paediatr. 2018; 89 (03) 189-199
• 15 Landau Z, Abiri S, Gruber N. et al Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real-life observational experience. Acta Diabetologica 2018; 55 (12) 1303-1310
• 16 Messaaoui A, Tenoutasse S, Crenier L. Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use. Diabetes Technol Ther 2019
• 17 Chase HP, Beck RW, Xing D. et al Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther 2010; 12: 507-515
• 18 Vesco AT, Jedraszko AM, Garza KP. et al Continuous Glucose Monitoring Associated With Less Diabetes-Specific Emotional Distress and Lower A1c Among Adolescents With T. 12 (04) 792-799
• 19 Biester T, Kordonouri O, Holder M. et al „Let the Algorithm Do the Work“: Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients. Diabetes Technol Ther 2017; 19 (03) 173-182
• 20 Thomakos P, Mitrakou A, Kepaptsoglou O. et al The Predictive Low Glucose Management System in Prevention of Clinically Significant Hypoglycemia in Type 1 Diabetes. A Preliminary Study Identifying the Most Common Events Leading Up to Hypoglycemia During Insulin Pump Therapy. Exp Clin Endocrinol Diabetes 2019 DOI: 10.1055/a-0889-7598
• 21 Richard M, Bergenstal MD, Satish Garg MD, Stuart A. et al Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA 2016; 316 (13) 1407-1408
• 22 Cordero TL, Garg SK, Brazg R. et al The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed^™ 670 G Hybrid Closed-Loop System. Diabetes Technol Ther 2017; 19 (12) 749-752
• 23 Anderson SM, Buckingham BA, Breton MD. et al Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia. Diabetes Technol Ther 2019; 21 (06) 356-363